Corrigendum to Rationale and trial design of NATALEE: a Phase III trial of adjuvant ribociclib + endocrine therapy versus endocrine therapy alone in patients with HR+/HER2- early breast cancer
- PMID: 37786535
- PMCID: PMC10541727
- DOI: 10.1177/17588359231201818
Corrigendum to Rationale and trial design of NATALEE: a Phase III trial of adjuvant ribociclib + endocrine therapy versus endocrine therapy alone in patients with HR+/HER2- early breast cancer
Abstract
[This corrects the article DOI: 10.1177/17588359231178125.].
© The Author(s), 2023.
Erratum for
-
Rationale and trial design of NATALEE: a Phase III trial of adjuvant ribociclib + endocrine therapy versus endocrine therapy alone in patients with HR+/HER2- early breast cancer.Ther Adv Med Oncol. 2023 May 29;15:17588359231178125. doi: 10.1177/17588359231178125. eCollection 2023. Ther Adv Med Oncol. 2023. PMID: 37275963 Free PMC article.
Publication types
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous